Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Publication | Open Access

DOI Full Paper Access

135

Citations

References

2018

Year

Michael Friedländer, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari Wenzel, Daniel Eek, Manuel Rodrigues, Andrew R. Clamp,

The Lancet Oncology

Olaparib MaintenanceHealth-related QualityMedicineCancer ManagementGynecologyOutcomes ResearchPatient-reported OutcomeRelapsed Ovarian CancerCancer TreatmentOncologyGynecology OncologyOvarian Cancer